High blood pressure continues to be a highly prevalent condition affecting about 20 percent of the US population. Untreated it may lead to coronary heart disease, stroke, kidney failure, and other complications. Medication is a major means of controlling hypertension and averting these debilitating consequences. Treatment with drugs, however, is undermined by suboptimal adherence to therapy. Forgetting to take medications is the most commonly elicited reason for lapses in medication use, but side effects, health beliefs, lack of knowledge of disease and treatment instructions, and financial barriers may also interfere. Determining those factors that (1) are predictably associated with fluctuations in adherence (such as day of the week, holidays, medical appointments), (2) ameliorate the impact of nonadherence such as pharmacologic properties of drugs that protect patients during adherence lapses, and (3) correlate with the accuracy of adherence reporting by patients will assist in anticipating and addressing adherence obstacles and serve as the objectives of the work proposed herein. To address these issues, this study will utilize data collected from electronic adherence monitors, questionnaires, and computerized medical records that contain blood pressure readings during a prior investigation of antihypertensive adherence (HS07821). This earlier investigation involved 286 members of Harvard Pilgrim Health Care, a large New England managed care organization, who were on single drug therapy for mild to moderate hypertension and was conducted from 1994 to 1997. Objective 1 will evaluate the impact of temporal factors such as weekend versus weekday, holidays, seasons, and impending medical appointments on adherence by analyzing their effects on the daily rate of dosing recorded by electronic medication monitors. Time trend models will be used for this purpose. Objective 2 will be addressed by assessing the impact of pharmacologic duration of action on the level of antihypertensive adherence required to maintain a goal blood pressure of less than 140/90 mmHg. This will involve determining if the relationship between adherence and blood pressure is modified by the duration of drug effect. Objective 3 concerning correlates of accuracy of reported adherence will be approached by verifying reported adherence against electronically measured adherence. Predictors and correlates of accurately reported adherence such as patient age, gender, race/ethnicity, education, socioeconomic status, health beliefs, and measures of health status will then identified by cross tabulating and statistical modeling accurate reporting against these factors.
| Choo, P W; Rand, C S; Inui, T S et al. (2001) A cohort study of possible risk factors for over-reporting of antihypertensive adherence. BMC Cardiovasc Disord 1:6 |
| Choo, P W; Rand, C S; Inui, T S et al. (2000) A pharmacodynamic assessment of the impact of antihypertensive non-adherence on blood pressure control. Pharmacoepidemiol Drug Saf 9:557-63 |
